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A B S T R A C T
Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior in
healthy subjects, which are similar to the state acute psychosis and are relevant in translational schizophrenia
research. Functional magnetic resonance imaging (fMRI) can be used for non-hypothesis-driven analysis of brain
connectivity. The correlation between clinical behavioral scores and neuroimaging can help to characterize
ketamine effects on healthy brains in resting state.
Method: seventeen healthy, male subjects (mean: 27.42 years, SD: 4.42) were administered an infusion with S-
Ketamine (initial bolus 1mg/kg and continuous infusion of 0.015625mg/kg/min with dosage reduction−10%/
10min) or saline in a randomized, double-blind, cross-over study. During infusion, resting state connectivity was
measured and analyzed with a seed-to-voxel fMRI analysis approach. The seed regions were located in the
posterior cingulate cortex, intraparietal sulcus, dorsolateral prefrontal cortex and fronto-insular cortex. Receiver
operating characteristics (ROC) were calculated to assess the accuracy of the ketamine-induced functional
connectivity changes. Bivariate Pearson correlation was used for correlation testing of functional connectivity
changes with changes of clinical scores (PANSS, 5D-ASC).
Results: In the executive network (ECN), ketamine significantly increases the functional connectivity with parts
of the anterior cingulum and superior frontal gyrus, but no significant correlations with clinical symptoms were
found. Decreased connectivity between the salience network (SN) and the calcarine fissure was found, which is
significantly correlated with negative symptoms (PANSS) (R2 > 0.4).
Conclusion: Decreased ketamine-induced functional connectivity in the salience network may qualify as accurate
and highly predictive biomarkers for ketamine induced negative symptoms.
1. Introduction
The NMDAR antagonist, S-Ketamine, is a widely used anesthetic and
analgesic agent in clinical practice (Niesters et al., 2012). In sub-anes-
thetic dosages, its effects on the central nervous system mimic positive
and negative symptoms in healthy subjects similar to acute psychosis or
schizophrenia while also exacerbating clinical symptoms in schizo-
phrenia patients (Lahti et al., 2001; Frohlich and Van Horn, 2014).
Therefore, ketamine is generally considered to be a useful
pharmacological model for glutamatergic dysfunction in schizophrenia.
Investigating ketamine-dependent changes of brain connectivity is a
promising approach to understand the underlying mechanisms of these
clinical symptoms. Furthermore, subanesthetic ketamine is a promising
medication for treatment resistant depression (Berman et al., 2000), but
it's still unknown, whether psychotomimetic side effects can be fully
segregated from the therapeutic effect (Maltbie et al., 2017). Ketamine-
induced changes of functional connectivity might be used as a surrogate
outcome measure (functional biomarker) when conducting drug trials
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to assess the dose-reponse relationship of psychotomimetic ketamine
effects. In an ideal scenario, the combination of imaging markers and
clinical parameters could be used to find dosages that minimize the
positive/negative symptoms while sufficiently treating patients, e.g.
with major depression.
In order to investigate ketamine effects on the brain a widely used
non-invasive approach to measure regional and global brain con-
nectivity with high spatial and temporal resolution is functional mag-
netic resonance imaging (fMRI). For example, fMRI can measure re-
gional brain activity indirectly by fluctuations in the blood‑oxygen-
level dependent (BOLD) signal within the brain vessels during an MR-
scan (Buxton, 2013). Recent studies suggest that neural activity and
perfusion stay coupled during subanesthetic ketamine infusion (Maltbie
et al., 2017).
Non-task related brain activity can be measured by using resting-
state fMRI (RS-fMRI) and connectivity analysis can reveal intrinsic
resting state networks, which show coherent fluctuations of BOLD-
signal. This method allows non-a priori hypothesis driven analysis of
the brain activity (Niesters et al., 2012). Recent fMRI research on ke-
tamine uses mainly two different analysis approaches: global brain
connectivity and seed-based analysis (Maltbie et al., 2017).
In global connectivity analysis an overall increase of resting-state
functional connectivity across widely distributed networks has been
reported for acute drug challenge (Driesen et al., 2013). This study
showed a correlation between positive schizophrenia symptom scores
and increased global connectivity in ketamine. Another study on global
connectivity by Joules et al, demonstrated overall decreased cortical
and increased subcortical functional connectivity (Joules et al., 2015).
Effects of sub-anesthetic ketamine administration on RS-fMRI
functional connectivity in healthy subjects were extensively in-
vestigated by recent research using Region of Interest (ROI)-analyses
(Scheidegger et al., 2016; Grimm et al., 2015; Khalili-Mahani et al.,
2015; Niesters et al., 2012; Scheidegger et al., 2012). These experi-
ments differed in dosage of administered ketamine, ranging from
0.25mg/kg body weight (Scheidegger et al., 2012) to 0.57mg/kg
(Niesters et al., 2012; Khalili-Mahani et al., 2015). Another difference
between the experiments was the period of RS-fMRI data acquisition,
ranging from simultaneous infusion and scan (e.g. Khalili-Mahani et al.,
2015) to control scans 24 h after infusion (Scheidegger et al., 2012). In
contrast to these studies, a different approach was chosen by Bon-
homme et al… by studying ketamine resting-state effects in different
clinical sedation levels of their subjects without a predefined ketamine
plasma levels (Bonhomme et al., 2016).
Acute ketamine challenge increases positive connectivity between
the hippocampus and the dorsolateral prefrontal cortex (DLPFC)
(Grimm et al., 2015). In another study, increased connectivity was
found between the hippocampus with cingulate, precuneal, cerebellar
and basal ganglia regions (Khalili-Mahani et al., 2015). By using an
amygdala seed an increased connectivity with the precuneal anterior
cingulate was reported (Scheidegger et al., 2016). Niesters et al selected
cortical seed regions only and showed increased functional connectivity
between the medial visual network with cerebellum and visual cortex.
Additionally, decreased connectivity was shown between the auditory
and somatosensory cortex on one hand and the amygdala, anterior
cingulate cortex (ACC) and insula on the other hand (Niesters et al.,
2012). Within the default mode network (DMN), an overall decreased
connectivity was found 24 h after ketamine infusion between its re-
presentative hub, the posterior cingulate cortex (PCC) and the medial
prefrontal cortex and ACC (Scheidegger et al., 2012). By using a target-
controlled infusion approach with the Domino model, Bonhomme et al
reached different levels of sedation in their subjects from light sedation
to unresponsiveness (Bonhomme et al., 2016). Resting-state functional
connectivity in ROIs of the DMN, ECN, SN, auditory network, sensor-
imotor network and visual network was compared in these different
responsiveness states. It was shown that deeper sedation decreased
DMN functional connectivity, especially with the prefrontal cortex and
anticorrelated activity between the DMN and other brain regions was
significantly reduced as well. SN functional connectivity was decreased
by ketamine, but nonuniformly between subjects. The ECN functional
connectivity was minimally affected in the experiment.
Here, we conducted a double-blind, randomized, placebo-controlled
cross-over subanesthetic ketamine-drug challenge experiment in
healthy male subjects. It was the primary aim of this study to answer
the question whether ketamine-induced effects on functional con-
nectivity in resting state networks potentially qualifies as a surrogate
outcome measure (functional biomarker) to be used in research of ke-
tamine side effects, for instance in dosage-response studies of sub-
anesthetic ketamine. We investigated ketamine effects on RS-fMRI, as-
sessed its accuracy to predict drug effects and correlated drug effects on
functional connectivity with clinical symptom changes before and after
each scan session. For assessing symptom changes, we used the Positive
and Negative Symptom Scale of Schizophrenia (PANSS) (Kay et al.,
1987) and - for exploratory reasons - the Altered State of Consciousness
(5D-ASC) Rating Scale (Dittrich, 1998). We selected functional net-
works for a seed-to-voxel analysis that have been previously implicated
in schizophrenia (Woodward et al., 2011): the DMN, the dorsal atten-
tion network (DAN), the executive control network (ECN) and the sal-
ience network (SN) which are associated with memory, attention and
executive cognitive functions. These functional networks were identi-
fied as “higher functional networks” by recent research (Woodward
et al., 2011). The linkage between schizophrenia and ketamine effects is
particularly interesting for our study. Therefore, we aim to compare
both studies and focus exclusively on these large resting state networks.
2. Methods and materials
The study was conducted in compliance with the Ethical principles
of the WMA Declaration of Helsinki, the EU Clinical Trial Directive
2001/20/EC and the German Medicines Act (Arzneimittelgesetz).
Approval was obtained by the local ethics committee (Ärztekammer
Nordrhein, Düsseldorf, Germany) and by the German federal drug
agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM).
As a Phase-I study, this clinical trial was registered in the non-public
European Union Drug Regulating Authorities Clinical Trials (EudraCT)
repository.
2.1. Participants
As outlined in more detail elsewhere (Musso et al., 2011), male
volunteers were recruited via newspapers and the internet. Prior to
study inclusion, full written consent was obtained and a medical,
neurological and psychiatric examination (including assessment of Di-
agnostic and Statistical Manual of Mental Disorders (DSM)-IV Axis I/II
diagnoses) by a certified neurologist and psychiatrist were performed.
Twenty-four healthy male subjects participated in the study. Male
subjects were recruited exclusively to avoid additional screenings, e.g.
pregnancy tests, prior to the study. Research on functional connectivity
between interhemispheric corresponding brain regions in fMRI suggests
between-gender differences in resting state functional connectivity,
especially in the prefrontal cortex and amygdala Zuo et al., 2010).
While these differences would have been particularly interesting for our
study regarding ketamine effects, adding functional connectivity var-
iance to an analysis with a limited number of subjects, e.g. through
between-gender differences, was a major concern, possibly reducing the
sensitivity to ketamine effects.
Two subjects dropped out because of adverse events during first
scan session (panic attack, tachycardia), one was administered keta-
mine and the other one was administered placebo. N=5 subjects were
excluded from further analysis, because at least one RS-fMRI session
wasn't acquired. These subjects showed excessive head motion due to
positive symptoms (excitement, hallucinations…) during the ketamine
sessions, which therefore prematurely terminated by the study
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conductors. Subjects with prematurely terminated RS-fMRI scans wer-
en't excluded from further analysis. Overall, seventeen subjects (mean
age: 27.42 years, age range: 21–35 years, SD: 4.42) were included in
this analysis. All subjects except one were right handed. Exclusion cri-
teria were: age below 18 years or over 35 years, past medical history of
a medical, neurological, psychiatric or ophthalmic disease, drug med-
ication less than four weeks before the trial, history of drug abuse, first
or second degree relatives with schizophrenia, clinically relevant ab-
normalities in blood/drug test, claustrophobia, metal implants (pros-
thesis, cardiac pacemakers), missing written informed consent, ex-
cessive head motion during RS-fMRI echo planar imaging (EPI) session
(x, y or z-translation> 3mm compared to mean) and missing RS-fMRI
sessions.
2.2. Study design
This study was a randomized, double-blind, placebo-controlled
cross-over trial. On two separate scan sessions, the subjects were either
challenged with S-ketamine (Ketanest S, Pfizer Pharma PFE, Berlin,
Germany) and saline (0.9% NaCl) intravenously right before the start
and during the MR scan. There was at least a one week between the two
MRI scan sessions for each subject to avoid residual drug effects on the
cross-over scan. The order of ketamine or placebo sessions was ran-
domly assigned and counterbalanced. Upon arrival, subjects received a
psychopathological evaluation, which was performed by a psychiatrist
by using PANSS and 5D-ASC. The PANSS includes the following items:
“positive symptoms”, “negative symptoms” and “sum”. “Positive
symptoms” are defined by scale items like delusions, conceptional
disorganization, hallucinatory behavior, excitement, grandiosity, sus-
piciousness and hostility (Kay et al., 1987). “Negative symptoms” in-
clude blunted affect, emotional withdrawal, poor rapport, passive-
apathetic social withdrawal, difficulties in abstract thinking, lack of
spontaneity and stereotypical thinking (Kay et al., 1987). The 5D-ASC
was tested with the following subitems: “oceanic boundlessness” (OBN,
referring to dissolution of ego boundaries associated with positive
emotions), “dread of ego dissolution” (DED, distressing experience of
depersonalization, thought disorder and loss of body control), “vi-
sionary restructuralization” (VRS, e.g. visual illusions and hallucina-
tions), “auditory alterations” (AUA, e.g. illusions and hallucinations)
and “vigilance reduction” (VIR) (Studerus et al., 2010). This evaluation
was repeated directly after the MR scan. The subjects received an in-
travenous line and were transferred to the MR scanner. A bolus of
0.1 mg/kg S- ketamine (or equal volumes of saline) was administered,
then the infusion stopped for one minute after MR scan initiation and
continued during the scan with 0.015625mg/kg/min (max. one hour)
with a dosage reduction of 10% every 10min. This was performed in
order to maintain stable ketamine plasma levels during the experiment
as ketamine slowly accumulates during infusion (Feng et al., 1995).
Ketamine plasma levels were not measured during this experiment. But
the infusion regime was chosen to reach relatively stable plasma levels
and is derived from an earlier ketamine study (Umbricht et al., 2000).
By using the STANPUMP simulation software and the domino model for
ketamine, our infusion regimen was tested exemplarily for a twenty-five
years old male subject with 180 cm height and 80 kg weight (Shafer,
2008). Using a fixed infusion rate of 0.02mg/kg/min, which was used
due to the limited digit input of the software, plasma levels for keta-
mine were 0.4 μg/ml after one minute, lowest after five minutes with
0.25 μg/ml and were slowly increasing to 0.48 μg/ml after 90min
(longest period of infusion). Therefore, we can assume that the plasma
levels were between 0.25 μg/ml and lower than 0.48 μg/ml during the
whole experiment. The intravenous infusion was monitored by a board-
certified anesthetist. Additionally, vital signs (blood pressure, periph-
eral pO2-saturation and partial CO2-pressure) were monitored but
weren't recorded synchronously with the fMRI sessions and weren't
available for correlation testing in this analysis.
Fig. 1. Study Procedures: Seventeen subjects were randomly assigned to either ketamine or placebo (saline) infusion (cross-over: > one week apart).
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2.3. fMRI data acquisition
The MR scans were performed using a 3 T MR Scanner (Trio,
Siemens, Erlangen, Germany). The MRI scanning sequence consisted of
a structural MR scan during minute 0–7, a task-related MR sequence
using a visual oddball task (checkerboard reversal) from minute 8 to 34
(already published by Musso et al., 2011) and a resting-state EPI session
of 20min which is presented in the present paper (see Fig. 1). The
structural images were acquired by using the following settings: T1-
weighted MR sequence (magnetization-prepared rapid gradient-echo
sequence): repetition time/echo time=2250/3.03ms, flip angle= 9°,
176 sagittal slices, FOV 200×200mm, 64×64 matrix, voxel size
1× 1×1mm. The following MRI sequence parameters were used in
the EPI sessions (RS-fMRI): 33 slices; slice order: ascending, slice
thickness: 3 mm, field of view (FOV) 200×200mm, 64× 64 matrix,
voxel size: 3× 3×3mm, repetition time 3400ms, echo time 40ms,
flip angle 90°.
2.4. fMRI data processing
Prematurely terminated scan sessions during ketamine challenge
required shortening all scan sessions to the same length in order to
compare data between subjects. This approach was chosen to include
subjects showing more positive symptoms (e.g. excitement, hallucina-
tions) as well as less affected subjects equally without causing a selec-
tion bias by excluding subjects with prematurely terminated scans
during drug challenge. Furthermore, shorter sessions could potentially
reduce the influence of head motion on further analysis. The numbers
of all acquired RS-fMRI volumes for each condition are shown in
Table 1 with the shortest ketamine scan consisting of 163 volumes. All
data were shortened to the first 150 volumes (duration=8min 30 s)
for further analysis, excluding the first five volumes from each session
to minimize the influence of technical artifacts of the MRI scanner
(FEAT User guide, 2016). The overall analyzed resting-state period is
within the standard range of recent studies (3-11min) (Birn et al.,
2013). Shortening the sessions to the same length was performed to
avoid different resting-state periods as an additional source of con-
founds. The functional connectivity is calculated from signal correlation
between seed region and target area over a time course. Not only could
shortening or extending the time course between subjects cause a se-
lection bias, e.g. favoring more stable normal resting-state connectivity
over short instable ketamine effects in a less affected subject, but add
other between-subject confounds, e.g. vigilance reduction during longer
periods with closed eyes.
To compare the head motion of the included volumes between ke-
tamine and placebo, the six realignment parameters for translation and
rotation from the latter described fMRI preprocessing were tested for
significant differences of mean head motion and mean head rotation.
Mean head motion was calculated as mean value of all head displace-
ments per subject and session (displacement= square root
(x2+ y2+ z2)) and mean head rotation as the mean of all absolute
Euler angles for each subject and session (Euler angle= arccos((cos
(pitch)cos(roll) + cos(pitch)cos(yaw)+ cos(roll)cos(yaw)+ sin(pitch)
(sin(yaw)sin(roll) - 1)/2)) (Van Dijk et al., 2012).
Functional EPI data were preprocessed using Statistical Parametric
Mapping 12 (SPM 12, Wellcome Trust, London, UK). The following steps
were performed: 1) slice timing correction, 2) spatial realignment to
mean with rigid body correction (three translation and three rotation
parameters), testing for excessive head motion or rotation in any di-
rection (> 3mm or 3°), 3) coregistration of the structural image and the
functional data, 4) segmentation of brain tissues (grey matter, white
matter and cerebrospinal fluid (CSF)), 5) spatial normalization to
standard Montreal Neurological Institute (MNI) space and 6) smoothing
with full width at half maximum (FWHM)=8×8×8mm kernel.
2.5. FMRI analysis and ROC curves
Preprocessed data were analyzed by using the CONN connectivity
toolbox V15 (Gabrieli Lab, Massachusetts, USA). Experimental data of
all subjects were sorted into two groups (placebo or ketamine). For
reduction of motion related artifacts, session specific realignment
parameters from preprocessing were used as first level covariates.
Reduction of confounding noise signals was performed with CONN
standard processing steps including regression of CSF and white matter
BOLD-signals, despiking, nuisance regression of motion related com-
ponents via component-based noise correction method (CompCor),
linear detrending and band-pass filtering (0.008 to 0.09 Hz) before
connectivity analysis (Whitfield-Gabrieli and Nieto-Castanon, 2012).
Further correction of micro motion, e.g. by using scrubbing or wavelet
despiking, was not performed.
For seed-to-voxel analysis the seed ROIs were defined as 6mm ra-
dius spheres around MNI coordinates. The ROI volume size was chosen
accordingly to the values used in the publication by Woodward et al. At
a voxel size of 3x3x3mm, the 6mm radius of the spherical ROIs is a
compromise between avoiding overlapping between functionally dis-
tinct brain regions in a single seed region and including multiple voxels
in a ROI to represent cluster-wise activation rather than single voxel
activation. The ROIs are located in the following brain regions: PCC
(1–55 17) for the DMN, left and right intraparietal sulcus (−25–53 52 /
25–57 52) for DAN, left and right DLPFC (−42 34 20 / 44 36 20) for
ECN and left and right fronto-insular cortex (−32 26–14 / 38 22 10) for
SN (Woodward et al., 2011). For seed-to-voxel analysis, a seed mask
was created of each functional network including the ROIs for left and
right hemisphere. On single level for each ROI the mean BOLD-signal
time course was extracted, tested for correlation with every other voxel
in the brain using bivariate Pearson correlation. The correlation coef-
ficients were then Fisher r-to-z transformed and used to create z-score
correlation maps. On these maps second level voxel-wise statistics was
performed in CONN, using a general linear model. Several sources of
variance were removed by linear regression (e.g. white matter, CSF
signals) and two-sided between condition contrasts using paired-t-tests
were performed. For these voxel-wise statistics the following thresholds
were applied: False-discovery rate (FDR) corrected cluster extent
threshold p-value< 0.05 and “peak-level” uncorrected height
threshold p-value< 0.001. These thresholds are sufficient for correc-
tion of multiple comparisons (CONN FAQ, 2016). Resulting clusters of
interest are visually presented using BrainNet viewer (Beijing Normal
Table 1
Overview on all acquired resting state fMRI volumes of included subjects
(N= 17).
Subject number Placebo session Ketamine session
(number of volumes) (number of volumes)
1 400 400
2 400 400
3 400 202
4 400 204
5 400 320
6 400 315
7 400 199
8 400 290
9 400 163
10 400 200
11 400 400
12 400 400
13 315 320
14 400 241
15 400 200
16 400 302
17 400 400
Shortest session 315 163
Mean session length 395 291.53
Paired t-test p-Value 0.000249693
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University, Beijing, China). This fMRI data analysis is performed on one
data set, but for four different seed regions separately. Therefore, an
increased family-wise error rate is a major concern. By lowering the
cluster extent threshold after FDR-correction, from p < 0.05 to p-
value<0.0125 (Bonferroni correction, 0.05 α-value divided by number
of tested seed regions) for further analysis, the problem of multiple
testing is addressed. The first level z-scores of significant clusters of
interest from second level analysis with p < 0.0125 are extracted from
CONN for every subject and condition. Further statistical analysis was
performed using SPSS (IBM Corp., Armonk, NY, USA). Delta values are
calculated by subtraction of placebo z-scores from ketamine z-scores
(ketamine- placebo).
Receiver Operating Characteristic (ROC) curves were calculated for
these delta values to test their specificity and sensitivity to differentiate
placebo and ketamine condition.
2.6. Correlation testing with symptom scores
The PANSS and 5D ASC subitems were tested before and after every
scan session; therefore, delta values were calculated to represent
change of each subitem during the scan (postsession- presession value).
The PANSS and 5D-ASC subitems were tested for significant differences
in ketamine condition by using paired t-tests. For each subject, delta
values comparing both conditions (ketamine session - placebo session)
were calculated. Each delta value of a significant fMRI signal change in
first level analysis was tested for correlation with the according delta
value of a clinical score by using bivariate Pearson two-tailed correla-
tion p < 0.00625 (eight tests, p-level was adjusted for multiple com-
parison with Bonferroni correction). Additionally, correlation testing
between the delta of session lengths (ketamine- placebo) and delta
clinical scores (ketamine- placebo) was performed to rule out prema-
turely terminated sessions as significant source of confounds.
3. Results
3.1. Head motion
In Tables 2 & 3 mean head motion and mean absolute Euler angles
are represented, the distribution of values is visualized using boxplots
in Fig. 2. A group-level paired t-test for mean head motion and mean
rotation showed no significant difference between ketamine and pla-
cebo on group level (head motion p-value=0.967 and rotation p-
value= 0.526).
3.2. Ketamine effects on resting state functional networks
Second level correlation maps with no Bonferroni correction applied
are shown for each condition and seed region in Fig. 3. Only clusters
with positive correlations with the seed regions were found. Two-sided
contrast maps without Bonferroni corrected are shown in Fig. 4 and
Table 4. Increased correlation in the ketamine condition was shown for
the DLPFC (ECN) with Left (L.) anterior cingulum, L. superior frontal
gyrus, Right (R.) medial temporal lobe, R. angular gyrus and R. superior
temporal lobe. Decreased correlation was found with the calcarine fis-
sure bilaterally. The increased correlation with L. anterior cingulum, L.
superior frontal gyrus and the decreased correlation with L. calcarine
fissure survived Bonferroni correction. No increased correlation in ke-
tamine condition was found for the fronto-insular cortex (SN), but de-
creased correlation with the R. calcarine fissure (this survives Bonfer-
roni correction) and L. frontal gyrus. The infraparietal sulcus (DAN)
showed increased correlation with the L. precentral gyrus, but no de-
creased correlation in ketamine condition. The posterior cingulate
cortex (DMN) showed increased correlation with the superior parietal
lobule and decreased correlation with the L. Rolandic operculum in
ketamine condition. For the results, which survived Bonferroni cor-
rection boxplots showing differences of delta z-scores on group level
between conditions are shown in Fig. 5. For the four correlations, which
survive Bonferroni correction ROC curves were calculated presented in
Fig. 6. For this specific experiment changes of the fMRI correlations
were highly specific and sensitive to differentiate between ketamine
and placebo condition with Area under the Curve (AUC)=0.934 for
ECN-anterior cingulum, 0.869 for ECN- superior frontal gyrus, 0.818 for
ECN- calcarine fissure and 0.862 SN- calcarine fissure. The increased
correlations due to Ketamine were slightly more specific and sensitive
than the negative correlations.
3.3. Correlation testing with symptom scores
The mean delta values of the clinical scores of PANSS and 5D-ASC
are shown for ketamine and placebo separately in Table 5, all subitem
values of the tested clinical scores were significantly increased by ke-
tamine. Three significant correlations between a clinical symptom score
and correlation changes were found (shown in Table 6): negative
symptoms (PANSS) with ECN-L. calcarine fissure as well as with SN- R.
Table 2
Mean motion of subjects (N= 17) calculated as mean of all displacements ac-
cording to realignment parameters (displacement= square root (x2+ y2+ z2))
in mm.
Subject no. Placebo Ketamine
1 0.317 0.637
2 0.619 0.393
3 0.416 0.930
4 0.336 0.264
5 0.295 0.325
6 1.435 0.614
7 0.234 0.285
8 0.223 0.756
9 1.294 0.455
10 1.518 0.900
11 0.316 0.216
12 0.422 0.756
13 1.089 0.499
14 0.327 1.447
15 0.406 0.256
16 0.382 0.700
17 0.543 0.651
Mean value 0.598 0.593
Paired t-test p-Value 0.967
Table 3
Mean Euler angle of rotation of subjects (N=17) calculated as mean of all
absolute Euler angles (Euler angle= arccos((cos(pitch)cos(roll) + cos(pitch)
cos(yaw)+ cos(roll)cos(yaw)+ sin(pitch)sin(yaw)sin(roll)− 1)/2)).
Subject no. Placebo Ketamine
1 0.016 0.007
2 0.017 0.009
3 0.014 0.012
4 0.030 0.010
5 0.013 0.011
6 0.027 0.033
7 0.005 0.005
8 0.004 0.035
9 0.016 0.011
10 0.054 0.011
11 0.015 0.009
12 0.012 0.017
13 0.014 0.004
14 0.005 0.017
15 0.016 0.005
16 0.008 0.011
17 0.007 0.024
Average 0.016 0.014
Paired t-test p-Value 0.526
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calcarine fissure and VIR with DMN- L. superior parietal lobule. Only
the correlation SN- R. calcarine fissure with negative symptoms
(PANSS) survived more stringent Bonferroni correction. The correlation
is shown in a scatter plot in Fig. 7. There is a positive correlation be-
tween functional connectivity and the clinical score. There was no
significant correlation between shortened sessions lengths in ketamine
condition and altered clinical symptom scores on group level, see
Table 7.
4. Discussion
In the present study, we investigated subanesthetic ketamine effects
on four RS-fMRI networks in healthy subjects with an fMRI analysis
which is comparable to the analysis approach used in a recent schizo-
phrenia study (Woodward et al., 2011). Head motion, a major source on
confounds in fMRI studies, wasn't significantly different between the
placebo and ketamine condition. After correction for multiple testing,
significant ketamine induced RS-fMRI signal changes remained with the
ECN and SN. The ECN seed showed increased functional connectivity
with resting network hubs, such as the anterior cingulum and the
frontal gyrus. This can be interpreted as overall increased connectivity
of the prefrontal cortex with other resting-state networks via these
hubs. We hypothesize that this effect is caused by disinhibition of
pyramidal neurons through blockade of NMDARs on GABAergic inter-
neurons which are abundant in the prefrontal cortex (Dawson et al.,
2013). Increased metabolic activity in the prefrontal cortex, shown in
mice using 2-deoxyglucose based imaging after application of 0.31mg/
kg/h body weight ketamine, supports this theory (Dawson et al., 2013).
Other significant ketamine-induced RS-fMRI signal changes were
the decreased connectivity of the ECN and SN seed with the calcarine
fissure in the occipital lobe, which represents a part of the primary
visual cortex (Griffis et al., 2016). As these regions are associated with
attention and executive functions, we interpret the decreased con-
nectivity with an area being involved in visual information processing
as a sign of decreased visual perception in these subjects. Physiologi-
cally, vision is processed from the primary visual cortex via the tem-
poral cortex (ventral stream) or parietal cortex (dorsal stream) (Van
Polanena and Davarea, 2015). Therefore, functional connectivity be-
tween frontal areas, such as SN or ECN, is generally not directly ex-
pected. Due the localization of the calcarine fissure close to the skull,
results are more prone to motion artifacts, (Havsteen et al., 2017)
though significant differences of motion weren't found. Our finding
could also be interpreted as impaired NMDAR-related neural
transmission between certain brain areas, including an area of visual
processing. We are not aware of any earlier study reporting a com-
parable finding for these two networks. However, taking a similar ROI-
analysis approach, Niesters et al reported ketamine-induced decreased
functional connectivity in the somatosensory network in a variety of
regions including occipital cortex whereas no such decrease of func-
tional connectivity was seen in other networks (Niesters et al., 2012).
Notably, these authors also did not observe any positive or negative
ketamine effect on the DMN, similar to our findings. This suggests that
ketamine-induced changes may not be seen in every network and that
the direction of ketamine effects might be dependent on the particular
network of investigation. As our findings aren't correlated with in-
creased positive symptoms, e.g. delusions and visual hallucinations,
these observations require further investigation in future research.
The negative symptoms (PANSS) were positively correlated with the
SN and calcarine fissure connectivity. Subjects with minimal difference
between pre- and postsession PANSS score showed increased negative
connectivity. This result could indicate increased inhibition of the vi-
sual cortex by ketamine, similar to the results by Yu et al. in chronic
ketamine administration in monkeys (Yu et al., 2012). Due to the ex-
citatory effects of ketamine on the interneurons in the frontal brain, this
effect could be indirectly caused by activation of inhibitory neurons in
another brain region projecting on the primary visual cortex. Increased
negative symptoms, e.g. decreased reactivity to stimuli, could be signs
of disrupted information processing in areas of attention, e.g. the SN.
We hypothesize, the inhibition of the visual cortex- SN connectivity by
ketamine reduces this troubled information processing by reducing
input to the SN, therefore subjects with strongly negative effects on
functional connectivity show decreased negative symptoms. This could
be a sign that the effects of ketamine differ regionally from excitation to
inhibition. The inhibition of connectivity of the ECN and SN with the
occipital love in subjects with high negative symptom scores suggests
that negative symptoms are caused by neuronal inhibition and are
specific to parts of executive control and sensory areas. But this hy-
pothesis requires further research on fMRI connectivity changes be-
tween subjects with high negative symptoms against low negative
symptoms. In this study such an analysis couldn't be performed, due to
a limited number of data sets. On the other hand, positive symptoms are
likely caused by excitation/ loss of inhibition in different brain areas.
Our analysis didn't reveal significant correlations between positive
symptoms and altered connectivity, so positive symptoms may be
caused by other brain regions, e.g. subcortical areas, or within region
that didn't show significant alterations in our analysis, but could be
Fig. 2. Boxplots for group mean values of head motion and head rotation compared between both conditions. P-value of paired t-test between groups indicates no
significant differences of mean values. (N= 17).
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affected nevertheless, like the DMN.
In contrast to Bonhomme et al., we didn't find a strong influence of
ketamine on the DMN. Furthermore, we didn't find any anticorrelations
in contrast to their publication. We hypothesize that the PCC seed in
our study doesn't represent the whole DMN and additionally seed re-
gions, e.g. the ACC, would have helped to analyze ketamine effects on
the DMN more precisely, especially in the frontoparietal part. The
finding that anticorrelation gets diminished in deeper sedation could be
a reason it wasn't a finding of the present study. In our study, dosages
and not the sedation levels were defined, therefore some subjects might
have had a deeper level of sedation than others, causing the antic-
orrelations not to be significant on group level.
Fig. 3. Separate ketamine and placebo effects in N=17 healthy subjects. Shown are positive effects (positive signal correlation of BOLD signal between seed regions
and other brain voxels) with second level result maps of seed-to-voxel analyses for all four networks: ECN, SN, DAN and DMN. The seed regions of each network are
indicated as green circles. Significant results without additional Bonferroni correction of thresholds. No negative ketamine effects (negative signal correlation of
BOLD signals) were observed. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Between conditions second level contrast maps with significant results without Bonferroni correction applied. Positive contrasts (ketamine>placebo) are
shown in red colors and negative contrasts (placebo> ketamine) are shown in blue for each seed region in the same figure. (Note: SN only showed significant
negative contrasts and DAN only positive contrasts; see Table 1). (N= 17). (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
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In recent RS-fMRI ketamine studies, whole-brain connectivity and
region-specific analysis approaches were both used to investigate ke-
tamine effects. In contrast to region-specific approaches, e.g. ROI-ana-
lysis, which was used in our study, whole-brain analysis doesn't require
a priori-hypotheses about pharmacological effects like preselected seed
regions. Recently, two studies were conducted to determine global ke-
tamine effects on resting fMRI connectivity using a “degree of cen-
trality”-analysis (Joules et al., 2015) and a “global-based connectivity”
(GBC) (Driesen et al., 2013). Joules and Coworkers reported ketamine
shifts brain connectivity from a cortical to a subcortical brain state with
a decrease of connectivity of cortical hubs (Joules et al., 2015). In
contrast, GBC-analysis showed ketamine-dependent increased global
connectivity both in cortical and subcortical regions with no discrete
clusters of increased GBC within this overall pattern. A number of re-
gions identified by GBC in the ketamine condition predicted positive
symptoms. Most notably, a correlation between increased connectivity
in thalamus and striatum on one side with reduced negative symptoms
of the PANSS on the other side was also observed (Driesen et al., 2013).
In our study, global effects of ketamine weren't measured as we at-
tempted to identify specific regions affected by drug challenge. How-
ever, increased connectivity, especially with the ECN, is consistent with
the reported global effects. We found no significant correlations of
ketamine-induced increase of connectivity with the PANSS positive
symptoms scale. Reasons for the discrepant findings could be related to
differences in the study designs. They administered a ketamine dose
which was considerably higher compared to the dosage chosen in our
study and therefore more likely to cause strong clinical effects. Never-
theless, the increase of positive and negative symptoms in our study
were significantly larger than reported in the mentioned study. Apart
from these study design considerations, our hypothesis-based approach
with preselection of functional networks might have been too con-
servative to detect statistically significant correlations with the PANSS
positive symptom score. Using cortical seeds exclusively may also ac-
count for our inability to detect ketamine-induced increases of
Table 4
Resting-state network alteration comparison between ketamine and placebo condition; Bonferroni
correction not applied.
MNI
coordinates
cluster
size cluster peak 
network
(seed region) contrast brain region X Y Z
in
voxels p-FDR p-unc T Beta
Execuve
control
network
Ket>Pla L. anterior cingulum -9 50 14 109 0.000009 0.00002 6.49 0.25
(le+right
dorsolateral L. superior frontal gyrus -24 59 11 47 0.003094 0.000139 5.82 0.22
prefrontal
cortex) R. medial temporal lobe 54 -25 -13 35 0.025101 0.000012 6.97 0.18
R. angular gyrus 51 -46 32 32 0.037861 0.0000024 6.15 0.25
R. superior temporal
lobe 63 -10 8 25 0.041278 0.000012 6.44 0.22
Ket<Pla L. calcarine fissure -6 -79 14 58 0.000789 0.000003 5.51 0.29
R. calcarine fissure 21 -67 11 22 0.046823 0.000097 4.95 0.2
Salience
network Ket>Pla no significant results - - - -
(le+ right
fronto-
insular
Ket<Pla R. calcarine fissure 3 -64 20 80 0.000065 0.000034 5.93 0.32
cortex) L. frontal gyrus -9 50 26 30 0.012562 0.000153 5.09 0.3
Dorsal
aenon
network
Ket>Pla L. precentral gyrus -45 8 38 39 0.018011 0.000003 6.39 0.26
(le+ right
infraparietal
sulcus)
Ket<Pla no significant results - - - -
Default
mode
network
Ket>Pla L.superior parietal lobule -15 -70 44 22 0.047821 0.000048 6.18 0.15
(posterior
cingulate
cortex)
Ket< Pla L. Rolandic operculum -60 11 5 29 0.040535 0.000055 5.87 0.27
Grey background indicates significant contrasts after Bonferroni correction. Ket>Pla contrast represents
Ketamine over Placebo between condition contrast calculated with paired t-test (p < 0.05). Ket< Pla
contrast represents Placebo over Ketamine contrast in second level analysis.
Abbreviations: Cluster p-FDR (cluster level p-value false discovery rate corrected), peak p-unc (peak level p-
value uncorrected), T (t-value of one sample t-test), Beta (fisher transformed correlation coefficients be-
tween seed and target area).
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subcortical connectivity being positively correlated with PANSS posi-
tive symptoms and negatively correlated with PANSS negative symp-
toms as reported by Driesen et al.
In drug research and development, ketamine is a widely used model
substance to mimic clinical symptoms of acute schizophrenia in healthy
subjects (Frohlich and Van Horn, 2014). However, the question is
whether ketamine-induced changes of RS-fMRI can serve the purpose as
a pharmaco-imaging model of schizophrenia. When comparing findings
with the results of a schizophrenia study (Woodward et al., 2011), it is
difficult to reconcile the findings in schizophrenia patients with our
ketamine findings. Differences between both studies are particularly
obvious in the DMN. In contrast to our findings, Woodward and col-
leagues showed an altered DMN resting network connectivity pattern in
patients with schizophrenia, with functional connectivity of the DMN
being increased involving several brain regions, e.g. including the
middle frontal gyrus, inferior gyrus and middle temporal lobe. Another
observation by them was a decreased DN and ECN functional con-
nectivity in schizophrenia patients in contrast to the increased ECN
connectivity in our study. The differences compared to the findings of
Woodward et al can't be explained by different seed regions and could
be explained by long-term effects of schizophrenia on connectivity
compared to acute ketamine symptoms.
4.1. Limitations
Limitations of our study were the selection of male subjects, redu-
cing the results of this study to being only applicable to half of the
population. A large number of missing or prematurely terminated ke-
tamine RS-fMRI sessions limited the number of usable data sets.
Shortening the session to a similar length causes a selection bias since
strong clinical ketamine effects (associated with e.g. excitement, hal-
lucinations) were less likely to be included in this analysis. The ex-
perimental approach with assessment of clinical scores before and after
each scan also did not allow to determine the exact onset of ketamine-
induced clinical symptoms, likewise ketamine plasma concentration
levels were not measured during our experiment. Furthermore, the
dosage of ketamine infusion was rather low compared to other studies.
Important vital signs, e.g. blood pressure, pO2-saturation and partial
CO2-pressure were monitored but weren't available for our fMRI ana-
lysis. These data could have been useful for conclusions on the clinical
Fig. 5. Ketamine vs. placebo condition (N=17 subjects, cross-over): Boxplots of single level results for the all contrasts of second level analysis that are significant
after Bonferroni correction. Functional connectivity (delta Fisher's Z-score (ketamine- placebo)). (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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effects of ketamine during the scan and for the differentiation between
subjects with more clinical symptoms and lesser symptoms. Using a
seed-to-voxel approach with predefined ROIs reduces the possibilities
for discovering all ketamine induced changes and selection of seeds
limited the findings to cortical areas exclusively. The extrapolation of
intrinsic activity of resting-state network from single seeds may not
necessarily be representative for the whole network. Additionally, RS-
fMRI lacks cognitive specificity; therefore, finding significant drug
effects in small data sets is impeded. Future research should address the
question, whether these findings are robust in other experiment.
5. Conclusion
In summary, we found significant ketamine effects on two RS-fMRI
functional networks (executive control network, salience network) with
high accuracy. Among these, positive ketamine effects were found in
Fig. 6. ROC curves for significant contrasts of second level analysis (after Bonferroni correction). Functional connectivity (delta Fisher's z-score) is used as parameter
to differentiate between ketamine and placebo condition.
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the ECN, which is consistent with our hypothesis of increased func-
tional connectivity of the prefrontal cortex. The clinical symptom scores
5D-ASC and PANSS also were significantly increased in ketamine con-
dition. However, the major finding is decreased functional connectivity
between SN and calcarine fissure being strongly correlated with nega-
tive symptoms. This suggests that this decreased functional connectivity
might be a possible surrogate outcome biomarker for negative symp-
toms in future ketamine drug trials.
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Table 6
Correlation testing between brain connectivity and clinical symptom score by using bivariate Pearson
correlation (p < 0.05). Grey background indicates result significant after Bonferroni correction.
brain connecvity
(seed region to cluster of interest) clinical symptom score
Pearson
correlaon r
significance
level p
Execuve control network
and R. calcarine fissure (21 -67 11)
Negave symptoms in
PANSS 0.511 0.036
Salience network
and R. calcarine fissure (3 - 64 20)
Negave symptoms in
PANSS 0.645 0.005
Default mode network
and L. superior parietal lobule (-15 -
70 44)
Visionary
restructuralizaon (VIR) 0.526 0.03
Table 7
Seventeen subjects, group level correlation testing between delta of number of
volumes (ketamine- placebo) and delta clinical symptom scores (ketamine-
placebo) by using bivariate Pearson correlation (p < 0.05). No Bonferroni
correction applied.
Parameter Pearson correlation r Significance level p
Positive symptoms 0.041 0.875
Negative symptoms 0.208 0.423
Sum 0.067 0.797
OBN 0.305 0.797
DED 0.224 0.388
VRS 0.053 0.84
AUA 0.0001 0.999
VIR 0.17 0.948
Abbreviations: “oceanic boundlessness” (OBN), “dread of ego dissolution”
(DED), “visionary restructuralization” (VRS), “auditory alterations” (AUA) and
“vigilance reduction” (VIR).
Fig. 7. Correlation testing between clinical symptoms and functional con-
nectivity: Significant correlation between the PANSS negative symptom delta
score (ketamine- placebo) and the SN- R. calcarine fissure functional con-
nectivity (delta Fisher's Z-score ketamine- placebo for each subject). 95% CI is
indicated by dotted lines and linear regression straight line with functional
equation in solid line.
Table 5
Seventeen subjects, comparison of clinical symptom scores and sub-items
between ketamine and placebo condition with repeated measure t-tests.
5D-ASC subitem scores were divided by 10 for better visualization.
Parameter Placebo Ketamine T P
mean (SD) mean (SD)
PANSS sum 0 (0) 41.71 (19.40) 8.6 < 0.0001
PANSS positive 0 (0) 10.29 (6.65) 6.19 < 0.0001
PANSS negative 0 (0) 8 (4.98) 6.42 < 0.0001
OBN 1.88 (5.10) 104.8 (56.31) 7.47 < 0.0001
DED 2.43 (5.11) 79.59 (47.22) 5.99 < 0.0001
VRS 1.60 (2.93) 55.56 (41.07) 4.49 < 0.0001
AUA 1.25 (2.39) 41.23 (39.30) 4.32 < 0.0001
VIR 4.14 (7.54) 60.96 (25.76) 5.19 < 0.0001
Abbreviations: “oceanic boundlessness” (OBN), “dread of ego dissolution”
(DED), “visionary restructuralization” (VRS), “auditory alterations” (AUA)
and “vigilance reduction” (VIR).
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